Objective Investigate the compatible stabilities of Sodium Glucuronic Acid Injection and Ganlixin Injection.Methods The Sodium Glucuronic Acid Injection mixed with Ganlixin Injection,to study the content of Sodium Glucuronic Acid Injection and Ganlixin Injection in different time by uv spectrophotometry,Investigate the appearance of the mixed solution,detect PH values and Insoluble Particles.Results At experimental temperature(15℃),the mixed solution,PH values,Insoluble Particles and the relative percentage have no obvious change in 4 hours.Conclusions The Sodium Glucuronic Acid Injection mixed with Ganlixin Injection is stabilization,so Sodium Glucuronic Acid Injection can combined with Ganlixin Injection.

Objective To approach the clinical effect and safety of glutathione in patients with alcoholic liver disease(ALD).Method The patients were divided into two groups, including the control group and treatment group.Two groups are all treated with routine therapy such as Ganlixin,potassium magnesium aspartate,mulivitamins and so on,the treatment group add glutathione,to inspect clinical menifetation and liver function changes of two groups before and after treatments.Result Among the treatment group,43.6%showed notable effective result,51.3%effective,the total dffective rate is 94.9%. Among the control group, 19.4%showed notable effective result, 58.3%effective,the total dffective rate is 78.7%.There is a significant different between the two groups (P

AIM:To observe the changes of hepatic fibrosis index,clinical symptom,physical sign and hepatic function after the patients were treated treatment with reduced glutathione hormone.METHODS:The 72 patients were divided into two groups that one was the treatment group with 37 patients and the other was the control group with 35 patients.The control group was accepted the treatment with Ganlixin Injection,Magnesium Aminosuccinate Injection and Mulvital,etc.The treatment group was accepted reduced glutathione hormone(1.5 g,once a day)in addition.The course of treatment lasted for 8 weeks.We observed the two groups' blood-serum fibrosis indexes(HA,LN,PIII-P,C-IV)and biochemistry indxes(TBIL,ALT,AST,GGT)before and after the treatment.RESULTS:The improvements of the treatment group were much better than the control group on the sides of clinical symptom,physical sign,hepatic function and blood-serum fibrosis.The treatment group's blood-serum fibrosis indexes were much lower after the treatment(P

Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on ( 6), and -19: , we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
Adrenal Cortex Hormones ; adverse effects ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Antiviral Agents ; adverse effects ; therapeutic use ; Betacoronavirus ; isolation & purification ; Coronavirus Infections ; drug therapy ; Critical Illness ; Drug Therapy ; Humans ; Nutritional Support ; Pandemics ; Pneumonia, Viral ; drug therapy ; Probiotics ; administration & dosage